Results 1 to 10 of about 4,658 (111)

Lifetime cost-effectiveness of lecanemab for early Alzheimer’s disease [PDF]

Frontiers in Public Health
IntroductionLecanemab is the second anti-amyloid-β monoclonal antibody to receive FDA approval for the treatment of early Alzheimer’s disease (AD), following aducanumab.
Xiangxiang Jiang, Gang Lv, Morgan E. Mendes, Jun Wu, Jing Yuan, Z. Kevin Lu   +5 more
doaj   +2 more sources

A prospective real‐world study of the efficacy and safety of aducanumab in China: Focus on early‐onset and autosomal dominant Alzheimer's disease [PDF]

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
INTRODUCTION Aducanumab is the first anti‐amyloid therapy used for Alzheimer's disease (AD) in China. METHODS This 12‐month, single‐center, real‐world study enrolled 12 participants with early AD receiving aducanumab 10 mg/kg every 4 weeks ...
Jinwen Xiao, Binyin Li, Biao Li, Jintao Wang, Ran Tang, Chao Gao, Xiangqian Che, Xiaomeng Xu, Shengdi Chen, Rujing Ren, Gang Wang   +10 more
doaj   +2 more sources

Is Aducanumab for LMICs? Promises and Challenges

Brain Sciences, 2021
Aducanumab, a human monoclonal antibody, was approved in June of 2021 as the first disease-modifying treatment for Alzheimer’s disease by the United States Food and Drug Administration (U.S. FDA).
Mohd Farooq Shaikh, Thaarvena Retinasamy, Chamath Gunawardena   +2 more
exaly   +3 more sources

Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab

Frontiers in Aging Neuroscience, 2022
Alzheimer’s disease (AD) is the most prevalent form of age-related dementia in the world, and its main pathological features consist of amyloid-β (Aβ) plaque deposits and neurofibrillary tangles formed by hyperphosphorylated tau protein.
Ming-Chao Shi, Fengna Chu
exaly   +3 more sources

Pharmacological and Clinical Heterogeneity of Anti-Amyloid Monoclonal Antibodies in Early Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Randomized Trials [PDF]

Medical Sciences
Background: Anti-amyloid monoclonal antibodies represent the first disease-modifying therapeutic strategy targeting amyloid-β pathology in early Alzheimer’s disease (AD).
Albert Vamanu, Alexandra Mastaleru, Thomas Gabriel Schreiner, Gabriela Popescu, Adina Maria Roceanu, Andrei Ionut Cucu, Alexandru Patrascu, Georgiana-Anca Vulpoi, Robert-Valentin Bilcu, Romica Sebastian Cozma, Raluca Olariu, Cătălina Elena Bistriceanu, Roxana Covali, Dan Iulian Cuciureanu, Alin Ciubotaru   +14 more
doaj   +2 more sources

Worth their weight in gray matter? A narrative review of cost‐effectiveness analyses of monoclonal antibodies for Alzheimer's disease [PDF]

Alzheimer’s & Dementia: Translational Research & Clinical Interventions
INTRODUCTION Monoclonal antibodies (mAbs) for Alzheimer's disease (AD) represent major therapeutic advances, but their economic value is uncertain.
Tuyet Thao Nguyen, Bozhidar T. Chakalov, Megan Van Noord, Charles DeCarli, Jeffrey S. Hoch   +4 more
doaj   +2 more sources

Increased risk of infusion‐related reactions switching between monoclonal antibodies for Alzheimer's disease: A case series [PDF]

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
INTRODUCTION Monoclonal antibodies (mAbs) targeting amyloid plaques are increasingly used in early Alzheimer's disease (AD). Infusion‐related reactions (IRRs) are recognized class effects, yet little is known about their occurrence when switching between
Ganesh Gopalakrishna, Cristina Tandoc, Pallavi Joshi   +2 more
doaj   +2 more sources

Aducanumab binds high molecular weight soluble Aβ oligomers and restores intracellular calcium levels [PDF]

Alzheimer’s Research & Therapy
Background Alzheimer's disease (AD) is characterized by amyloid-beta (Aβ) accumulation, leading to the formation of neurotoxic soluble oligomers (AβOs) that impair calcium homeostasis in neurons and astrocytes.
Lu Yu, Xueying Wang, Tri H. Doan, Yutian Fan, Thierry Bussiere, Brian J. Bacskai, Ksenia V. Kastanenka   +6 more
doaj   +2 more sources

Comparative efficacy and safety of symptomatic therapy and disease-modifying therapy for Alzheimer’s disease: a systematic review and network meta-analysis [PDF]

Frontiers in Neuroscience
BackgroundThe management of Alzheimer’s disease has shifted toward disease-modifying therapies aimed at delaying disease progression rather than focusing solely on symptomatic treatment.
Shiyu Liu, Shiyu Liu, Min Zhao, Min Zhao, Yuan Liu, Yuan Liu, Xin Yang, Xin Yang, Huayu Yan, Huayu Yan, Hongcai Xu, Hongcai Xu, Yabo Wu, Yabo Wu, Yumin Xu, Yumin Xu   +15 more
doaj   +2 more sources

Cost‐effectiveness of aducanumab to prevent Alzheimer's disease progression at current list price

Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2022
Introduction An estimated 6 million Americans have Alzheimer's disease (AD). Aducanumab was recently approved by the Food and Drug Administration despite the lack of clinical effectiveness data.
Pranay Sinha, Joshua A. Barocas
doaj   +1 more source